A therosclerosis and associated ischemic events are the leading cause of morbidity and mortality in industrialized countries. Atherosclerotic plaque formation is a multifactorial chronic inflammatory process characterized by the interaction of oxidized low-density lipoproteins (oxLDLs), endothelial cells, macrophages, T cells, and vascular smooth muscle cells (VSMCs). Atherosclerosis is initially driven by deposition in the arterial wall of oxLDLs, which provoke a chronic inflammatory response. Macrophages in the atherosclerotic plaque avidly internalize oxLDLs and become foam cells that critically contribute to plaque development by secreting a plethora of inflammatory mediators. [1] [2] [3] Human and animal studies have demonstrated that excessive cell proliferation in the arterial wall is a hallmark of atherosclerosis. 4, 5 Mammalian cell proliferation is controlled by a large number of proteins that regulate the cell cycle. Major positive regulators of cell proliferation are holoenzymes composed of a catalytic cyclin-dependent protein kinase (CDK) and a regulatory cyclin. Cell cycle progression is negatively regulated by CDK inhibitory proteins of the CDK interacting protein/kinase inhibitory protein (Cip/Kip; p21 Cip1 , p27 Kip1 , p57 Kip2 ) and inhibitor of CDK4 (Ink4: p16 Ink4a , p15 Ink4b , p18 Ink4c , p19 InK4d ) families. 6 Mitogen-induced downregulation of p27 Kip1 (p27) is critical for the activation of specific CDK-cyclin complexes, the subsequent transcriptional activation of genes required for the G 1 /S-phase transition, and the initiation of DNA replication. 7 In most cell types, the activity of p27 is regulated by posttranslational modifications that affect its stability and subcellular localization. 7, 8 Phosphorylation of p27 at serine 10 (p27phospho-Ser10) is a major mechanism of p27 regulation in different scenarios, 9 -15 and it has been estimated to be the most abundant posttranslational modification of p27 in cultured cells, accounting for 70% to 75% of its phosphate incorporation. 9 This phosphorylation event contributes importantly to p27 stabilization in the G 0 phase of the cell cycle 9, 11, [13] [14] [15] and promotes p27 exit from the nucleus in certain settings. 10, 12, 15, 16 p27 is a major negative regulator of cell proliferation in various pathophysiological settings, including cancer 17 and vasculoproliferative disease (eg, atherosclerosis and restenosis). 4, 18, 19 We have previously demonstrated that both global and hematopoietic cell-restricted inactivation of p27 accelerates diet-induced atherosclerosis in apolipoprotein E-deficient (apoEϪ/Ϫ) mice, coinciding with increased cell proliferation within the atheroma. 20, 21 The atheroprotective action of p27 in this animal model has been corroborated by others. 22 However, it remains unknown whether molecular mechanisms that limit p27's protective function indeed occur during human or experimental atherosclerosis. Moreover, although compelling in vitro evidence has emerged suggesting that p27 has cell cycle-independent activities, 23 the pathophysiological relevance of these activities, and in particular their possible atheroprotective role, remains unexplored. In the present study, we provide insight into these questions by demonstrating that p27-phospho-Ser10 is markedly reduced in human and mouse atherosclerosis and that expression of the nonphosphorylatable p27Ser10Ala mutant aggravates disease progression through a cell cycle-independent mechanism that involves increased RhoA/Rhoassociated coiled-coil containing protein kinase (ROCK) signaling and augmented foam cell formation.
Methods
See additional Methods in the supplemental material, available online at http://atvb.ahajournals.org.
Mice
Care of animals was in accordance with institutional guidelines and regulations. p27Ser10Ala knock-in mice 14 were backcrossed for more than 8 generations in a C57BL/6J background and then interbred with apoEϪ/Ϫ mice (C57BL/6J, Charles River) to generate apoEϪ/Ϫ p27Ser10Ala mice and apoEϪ/Ϫ littermates. After weaning, mice were maintained on a low-fat standard diet (2.8% fat, Panlab, Barcelona, Spain). For diet-induced atherosclerotic studies, 2-month-old mice were placed on atherogenic diet (10.8% total fat, 0.75% cholesterol, S4892-E010, Ssniff, Germany) for the indicated periods of time.
Quantification of Atherosclerosis Burden
Mice were euthanized and aortas were removed after in situ perfusion with PBS followed by 4% paraformaldehyde/PBS. Fixation was continued overnight at 4°C. An operator who was blinded to genotype quantified the extent of atherosclerosis by computerassisted morphometric analysis (SigmaScan Pro 5) of both wholemounted aorta stained with Oil Red O (O0625, Sigma, 0.2% Oil Red O in 80% MeOH) and hematoxylin/eosin-stained cross-sections of aortic tissue as previously described. 24, 25 
RhoA Activity Assay
RhoA activity in peritoneal macrophages obtained from 5-month-old mice fed standard chow (pool of 3 mice) was measured as the amount of RhoA-GTP using the absorbance-based RhoA G-LISA activation assay according to the manufacturer's instructions (BK-124, Cytoskeleton).
Analysis of Modified Low-Density Lipoprotein Uptake and Macrophage Foam Cell Formation
For modified acetylated low-density lipoprotein (acLDL) uptake studies, peritoneal macrophages from female fat-fed apoEϪ/Ϫ and apoEϪ/Ϫ p27Ser10Ala mice were incubated for 3 hours with Alexa Fluor 488 -labeled acLDL (1 g/mL, Invitrogen) in serum-free media. Cells were then collected and acLDL uptake was quantified by flow cytometry as the relative median fluorescence intensity. For in vivo oxLDL uptake by arterial macrophages, fat-fed mice received an intravenous injection of 20 g of diI-labeled oxLDLs (Biomedical Technologies). One day postadministration, mice were euthanized, and the aortas were digested as described. 26 Cells were then collected and stained with an Alexa Fluor 647-conjugated antibody against the macrophage-specific antigen F4/80 (Serotec). oxLDL uptake was quantified by flow cytometry as the relative median fluorescence intensity in F4/80-positive cells from aortic cell suspensions. For in vivo foam cell counting, freshly isolated resident peritoneal macrophages were plated on coverslips for 60 minutes and extensively washed to remove nonadherent cells. After fixation with 4% paraformaldehyde, cells were stained with Oil Red O and counterstained with hematoxylin.
Statistical Analysis
Data are presented as meanϮSEM. In experiments with 2 groups, statistical significance was evaluated using a 2-tailed, unpaired Student t test. Otherwise, a 2-way ANOVA with the Bonferroni post hoc test was performed (GraphPad Prism software). Differences were considered statistically significant at PϽ0.05.
Results

Reduced Level of p27-Phospho-Ser10 Is Associated With Atherosclerosis and Aggravates Disease Progression in apoE؊/؊ Mice
To gain insight into the potential role in atherosclerosis of p27 phosphorylation at Ser10, we first performed Western blot analysis in murine atherosclerotic arteries using a phosphospecific antibody. We found that p27-phospho-Ser10 is markedly downregulated in the atherosclerotic aortic arch of fat-fed apoEϪ/Ϫ mice (which exhibited prominent atherosclerotic lesions) compared with nonatherosclerotic tissue from age-matched controls fed standard chow ( Figure 1A ). To assess whether impaired p27-phospho-Ser10 is causally linked to atherogenesis, we interbred apoEϪ/Ϫ mice with p27Ser10Ala knock-in mice, which have both p27 alleles replaced by a version carrying a Ser3 Ala mutation at position 10 that blocks phosphorylation at this residue. 14 Figure 1C ). Likewise, we observed augmented atherosclerosis in cross-sections from the aortic sinus and 3 different regions of the ascending aorta separated by approximately 30 m ( Figure 1D ). Expression of p27Ser10Ala also increased atherosclerosis burden in fat-fed female apoEϪ/Ϫ mice (Supplemental Figure II) and in mice of both genders fed standard chow (Supplemental Figure III) . Overall, the relative content of macrophages and VSMCs in the atherosclerotic plaque was comparable in both genotypes, with the exception of a significant but very modest decrease in VSMC content in the ascending aortas of apoEϪ/Ϫ p27Ser10Ala mice ( Figure 2 ). Similarly, no significant differences were observed in the collagen content of atheromas (Supplemental Figure IV) . Collectively, these findings demonstrate that expression of the nonphosphorylatable p27Ser10Ala mutant hastens both native and dietinduced atherosclerosis development in male and female hypercholesterolemic apoEϪ/Ϫ mice.
Proatherogenic Effect of p27Ser10Ala Expression Is Cell Proliferation Independent
We have previously shown that genetic inactivation of p27 in apoE-null mice increases cell proliferation within atherosclerotic plaques and aggravates disease progres-sion. 20, 21 To assess whether p27Ser10Ala expression similarly affects neointimal cell proliferation, we performed immunofluorescence assays in the aortic sinus of fat-fed mice to detect expression of the proliferation marker Ki67 together with different cell-type specific antigens (smooth muscle ␣-actin for VSMCs, CD3 for T cells, Mac3 for macrophages). We noted similar percentage of neointimal Ki67-positive VSMCs ( Figure 3A ), T cells ( Figure 3B ), and macrophages ( Figure 3C ) in advanced plaques of both genotypes. Likewise, no significant differences were observed in the percentage of Ki67-immunoreactive Mac3positive cells in early fatty-streaks consisting mostly of macrophages ( Figure 3D ). Moreover, cultured bone marrow (BM)-derived macrophages of both genotypes exhibited similar cell-cycle kinetics (Supplemental Figure VA) in spite of lower p27 levels in apoEϪ/Ϫ p27Ser10Ala macrophages at all time-points analyzed (Supplemental Figure VB) . These findings suggest that expression of the nonphosphorylatable p27Ser10Ala mutant promotes atherosclerosis by a proliferation-independent mechanism. Reduced p27 phosphorylation at Ser10 is associated with murine atherosclerosis and accelerates disease progression in hypercholesterolemic mice. A, Western blot analysis of a pool of 6 aortic arches obtained from male apolipoprotein E-deficient (apoEϪ/Ϫ) mice fed either control chow (tissue essentially free of atheroma) or a high-fat atherogenic diet for 12 weeks (tissue with prominent atherosclerotic lesions). The p27-phospho-Ser10/p27 ratio was normalized to actin as loading control, and the average result of 3 different blots is shown (p27-pS10: p27 phosphorylated at serine 10). B to D, Male apoEϪ/Ϫ and apoEϪ/Ϫ p27Ser10Ala mice were fed a high-fat diet for 12 weeks. B, Plasma lipid levels before and after fat feeding. C, Atheroma size in the aortic arch and the thoracic aorta quantified by en face Oil Red O staining. Representative images are shown. D, Atheroma size quantified in histological sections from the aortic sinus and from 3 different regions of the ascending aorta (I, II, and III). Representative images of hematoxylin/ eosin-stained sections are shown below (atherosclerotic plaques delineated by discontinuous lines).
Expression of p27Ser10Ala in BM-Derived Cells Accelerates Atherosclerosis in apoE؊/؊ Mice
Given that macrophages are the most abundant cell type in atheromas of apoEϪ/Ϫ mice (cf. Figure 2 ) and play key roles in atherosclerosis, 1-3 we performed BM transplants to assess whether expression of the p27Ser10Ala mutant restricted to BM-derived cells affects the development of atherosclerosis. Lethally irradiated female apoEϪ/Ϫ mice were transplanted with male apoEϪ/Ϫ or apoEϪ/Ϫ p27Ser10Ala BM and then fed a high-fat diet for 8 weeks. Transplant efficiency in the BM was similar in both groups (apoEϪ/ϪBM: 88Ϯ12%; apoEϪ/Ϫ p27Ser10Ala-BM: 83Ϯ10%). Remarkably, atheroma size in the aortic arch and the thoracic aorta was increased in apoEϪ/Ϫ mice transplanted with apoEϪ/Ϫ p27Ser10Ala BM compared with apoEϪ/Ϫ BM ( Figure 4 ). These results demonstrate that abrogating p27-phospho-Ser10 specifically in hematopoietic cells is sufficient to aggravate atherosclerosis and suggest that this posttranslational modification plays an important role in the regulation of the atheroprotective actions that p27 exerts in macrophages, the most abundant BM-derived cell in the atherosclerotic plaque.
Expression of p27Ser10Ala in Macrophages Reduces p27 Total Levels But Increases Its Nuclear Localization
Previous studies have reported that p27Ser10Ala expression leads to decreased p27 protein levels by reducing its stability in quiescent fibroblasts and lymphocytes, 14, 15 and may also alter p27 subcellular localization by blocking its nuclear export. 10, 12, 15, 16 Consistent with these findings, we found a Ϸ2-fold reduction in total p27 protein levels ( Figure 5A ) and increased relative nuclear accumulation of p27 in apoEϪ/Ϫ p27Ser10Ala macrophages ( Figure 5B ).
Expression of p27Ser10Ala Increases RhoA/ROCK Signaling
The results presented thus far suggest that expression of p27Ser10Ala aggravates atherosclerosis via a cell proliferation-independent mechanism that operates in macrophages. Previous studies have shown that p27 can interact in the cytoplasm with the small GTPase RhoA, blocking its activation by Rho guanine nucleotide-exchange factors and thereby restricting signaling through the RhoA/ROCK pathway, 27 a major contributor to cardiovascular disease. 28, 29 To address whether p27Ser10Ala expression affects RhoA/ ROCK signaling, we first analyzed the degree of phosphorylation of the ezrin/radixin/moesin proteins (ERM), a reliable marker of the activity of this pathway. 30 Consistent with a previous study, 30 phospho-ERM was abundant in neointimal macrophages but absent in medial VSMCs ( Figure 6A ). Importantly, we found increased phospho-ERM in the atherosclerotic aortic arch of fat-fed apoEϪ/Ϫ p27Ser10Ala compared with apoEϪ/Ϫ mice ( Figure 6B ). Likewise, peritoneal macrophages obtained from fat-fed apoEϪ/Ϫ p27Ser10Ala mice exhibited increased phospho-ERM, as well as higher levels of GTP-bound-RhoA and cofilin phosphorylation, 2 additional markers of RhoA/ROCK activation ( Figure 6C ).
Expression of p27Ser10Ala Augments Modified Lipoprotein Uptake and Foam Cell Formation in a ROCK-Dependent Manner
We next investigated the internalization of modified lipoproteins by macrophages, an essential proatherogenic process that is facilitated by RhoA/ROCK signaling. 31 To this end, we analyzed in vitro the uptake of fluorescently labeled acLDL by resident peritoneal macrophages. We found increased uptake of acLDL in apoEϪ/Ϫ p27Ser10Ala macrophages, and this was blunted by pharmacological inhibition of ROCK with either Y-27632 or hydroxyfasudil ( Figure 7A ). We also observed increased 3 H-cholesterol accumulation in acLDLloaded p27Ser10Ala macrophages ( Figure 7B ) without significant effects on cholesterol efflux ( Figure 7C ). Supporting the in vivo relevance of these findings, we found increased uptake of diI-labeled-oxLDLs by macrophages within the atheroma of apoEϪ/Ϫ p27Ser10Ala mice, which almost reached statistical significance (Pϭ0.08) ( Figure 7D) , and a higher percentage of foam cells in peritoneal macrophages of fat-fed apoEϪ/Ϫ p27Ser10Ala mice ( Figure 7E ). The latter occurred without changes in the expression of either the prototypical scavenger receptors CD36 and scavenger receptor A or other membrane proteins that may mediate lipoprotein uptake, such as very-low-density lipoprotein receptor, toll-like receptor (TLR)2, TLR4, or lectin-like oxidized low-density lipoprotein receptor-1 (Supplemental Figure VI) , but coincided with increased bead phagocytosis by apoEϪ/Ϫ p27Ser10Ala macrophages, which was blunted by pharmacological inhibition of ROCK ( Figure 7F ).
Human Atherosclerotic Arteries Exhibit Reduced p27-Phospho-Ser10 and Increased ERM Phosphorylation
To address the clinical relevance of our findings, we examined the degree of phosphorylation of p27 and ERM in human coronary arteries (Figure 8 ). These studies revealed abundant p27-phospho-Ser10 in nonatherosclerotic vessels but undetectable levels in atherosclerotic specimens, which correlated with increased phospho-ERM in atherosclerotic arteries. These findings support the notion that loss of p27-phospho-Ser10 activates RhoA/ROCK signaling in human atherosclerotic arteries.
Discussion
Animal studies have demonstrated an important atheroprotective role of the tumor suppressor p27, which has been attributed to its function as a negative regulator of cell proliferation. 20, 21 Consistent with this idea, human studies revealed frequent colocalization of p27 and transforming growth factor-␤ receptors in atherosclerotic coronary arteries 32 and abundant expression of p27 in nonproliferating cells within both normal and atherosclerotic arteries. 33 However, the possibility that p27 exerts proliferation-independent activities in the arterial wall has not been analyzed to date, in spite of an increasing body of evidence suggesting that p27 modulates the activity of various signaling proteins other than CDKs and cyclins. It also remains largely unexplored whether changes in the expression or function of p27 occur during human or experimental atherosclerosis and are causally linked to disease progression. In this study, we address these questions by combining cell culture experiments and studies with atherosclerosis-prone apoEϪ/Ϫ mice and human specimens. To the best of our knowledge, we demonstrate for the first time the impairment of a posttranslational modification of p27 during atherosclerosis that might be causally linked to disease progression by limiting a proliferation-independent atheroprotective function of p27 in macrophages.
In most cell types, the activity of p27 is regulated by posttranslational modifications, predominantly phosphorylation at different residues. 7, 8 We previously found that atherosclerosis development is not affected in apoEϪ/Ϫ mice unable to phosphorylate p27 at threonine 187, 24 a posttranslational modification of p27 that controls its stability and function in several tissues and cell types. 7, 8 In this study, we assessed the role in atherosclerosis of p27 phosphorylation at Ser10, which appears to be the most abundant posttranslational modification of p27 and modulates its stability in different scenarios. 9 -15 Using a phospho-specific antibody that exhibits high specificity in Western blot (cf. Figure 5A ), we found a marked downregulation of p27-phospho-Ser10 in the atherosclerotic aortic arch of fat-fed apoEϪ/Ϫ mice versus nonatherosclerotic arteries of controls fed with standard diet. Supporting a cause-and-effect relationship between impaired p27-phospho-Ser10 and atherosclerosis, we found that expression of the nonphosphorylatable p27Ser10Ala mutant accelerates atherosclerosis in different vascular beds in apoEϪ/Ϫ mice of both genders fed either standard chow or high-fat diet. Our BM transplantation studies demonstrate that expression of the p27Ser10Ala mutant restricted to hematopoietic cells is sufficient to accelerate atherosclerosis development in apoEϪ/Ϫ mice, suggesting that lack of p27-phospho-Ser10 critically affects the function of macrophages in the vascular wall. Supporting this notion, we found reduced total p27 protein levels and increased nuclear p27 localization in cultured macrophages expressing p27Ser10Ala. These results are consistent with previous studies showing that expression of this nonphosphorylatable mutant reduces total p27 protein levels in fibroblasts and lymphocytes 14, 15 and affects p27's subcellular localization in some cell types by restraining its exit from the nucleus to the cytoplasm. 10, 12, 15, 16 We have previously shown that genetic disruption of p27 aggravates atherosclerosis in apoEϪ/Ϫ mice coinciding with increased VSMC and macrophage proliferation in the vessel wall. 20, 21 Moreover, mice lacking p27 exhibit increased body size and organomegaly, which have been attributed to increased cell proliferation. 34 -36 Therefore, we hypothesized that expression of p27Ser10Ala promotes atherogenesis by increasing neointimal cell proliferation. However, our studies revealed comparable amounts of proliferating VSMCs, T cells, and macrophages in advanced atherosclerotic lesions of fat-fed apoEϪ/Ϫ and apoEϪ/Ϫ p27Ser10Ala mice. Similarly, we found no differences in the proliferation of macrophages in early fatty streaks and similar kinetics of cell-cycle progression in cultured macrophages obtained from apoEϪ/Ϫ and apoEϪ/Ϫ p27Ser10Ala mice. Moreover, unlike p27-null mice, 34 -36 apoEϪ/Ϫ p27Ser10Ala mice have normal body weight. These results are consistent with previous studies showing that p27Ser10Ala expression does not affect body size or cell-cycle progression of lymphocytes and fibroblasts despite lowering p27 levels, 14, 15 suggesting that impaired p27-phospho-Ser10 does not affect cell proliferation. It is plausible that higher nuclear localization of p27 in cells expressing p27Ser10Ala compensates for the overall lower level of p27, thus allowing normal cell cycle progression. Supporting this notion, Besson et al reported that the p27Ser10Ala mutant exhibits increased interaction with CDK/cyclin complexes because of its nuclear accumulation. 15 Taken together, our previous results in apoEϪ/Ϫ mice lacking p27 20, 21 and the findings in apoEϪ/Ϫ p27Ser10Ala presented herein strongly support that p27 exerts both cell cycle-dependent and cell cycle-independent atheroprotective functions.
Having discarded abnormal cell proliferation as the mechanism underlying the aggravation of atherosclerosis in apoEϪ/Ϫ p27Ser10Ala mice, we examined whether p27Ser10Ala expression promotes atherogenesis by limiting a yet unidentified atheroprotective activity of p27 independent of its growth suppressive function. Indeed, p27 can regulate the activity of a number of regulatory proteins other than CDKs and cyclins. 27, 37, 38 We focused our attention on the small GTPase RhoA, which is inhibited through interaction with p27. 27 RhoA regulates a plethora of cellular processes via its downstream kinases ROCK1/2, 39 and strong evidence exists that activation of this pathway contributes to neointimal thickening in the setting of atherosclerosis, vessel ligation, and balloon angioplasty in different murine models. 28,29,31,40 -44 Our mechanistic studies provide the first evidence supporting a pathophysiologically relevant link between p27 and RhoA. We have shown that p27Ser10Ala expression augments RhoA/ROCK signaling in both atherosclerotic plaques of apoEϪ/Ϫ mice and in cultured macrophages. Moreover, apoEϪ/Ϫ p27Ser10Ala macrophages exhibit increased uptake of modified LDL and phagocytic activity, and these responses are blunted by pharmacological inhibition of ROCK1/2. These findings are consistent with previous studies showing that ROCK1 inactivation reduces foam cell formation 31 and that ROCK2 promotes phagocytosis. 45 We also found that the effect of p27Ser10Ala expression on lipoprotein uptake correlated with augmented accumulation of cholesterol and was not mediated either by reduced cholesterol efflux or by changes in the expression of scavenger receptors (including scavenger receptor A, CD36, lectin-like oxidized low-density lipoprotein receptor-1, verylow-density lipoprotein receptor, TLR2, and TLR4). Therefore, considering that the RhoA/ROCK pathway is involved in actin cytoskeletal remodeling during the engulfment of foreign material, 46 it is tempting to speculate that p27Ser10Ala macrophages exhibit RhoA-mediated cytoskeletal alterations that favor lipoprotein endocytosis/phagocytosis, leading to increased foam cell formation.
Supporting the clinical relevance of our findings, we found a marked reduction in p27-phospho-Ser10 level in atherosclerotic human coronary arteries. Human atherosclerosis was also accompanied by increased ERM phosphorylation in the arterial wall, suggesting augmented RhoA/ROCK signaling. On the basis of the results presented herein, we propose that scarce phosphorylation of p27 at Ser10 in the atherosclerotic plaque contributes to disease progression in a proliferationindependent manner, at least in part because of reduced p27 levels in macrophages, which lead to increased foam cell formation through RhoA/ROCK activation. When taken together with our previous studies with p27-null mice, 20,21 these findings indicate that p27 exerts both cell cycle-dependent and cell cycle-independent atheroprotective functions that could be potentiated by overexpressing p27 and preventing the loss of p27-phospho-Ser10, respectively. However, given that p27 overexpression may be expected to indiscriminately block cell proliferation and thus compromise plaque stability (eg, by decreasing the thickness of VSMC-containing fibrous caps), the development of drug-based therapies preventing the loss of p27-phospho-Ser10 merits further investigation. 
